ABPI President Pinder Sahota resigns 


Share post:

The Association of the British Pharmaceutical Industry (ABPI) has announced that Pinder Sahota has decided to step down as President of the ABPI.

ABPI stated that he has made this decision to “avoid an ongoing process around a Novo Nordisk ABPI Code of Practice breach becoming a distraction from the vital work of the ABPI”.

Richard Torbett, Chief Executive, ABPI, said: “Pinder is a passionate advocate for the industry, and I want to thank him for his valuable contribution as ABPI President.

“I fully respect Pinder’s decision to step down as ABPI President which will in no way affect the ongoing case relating to Novo Nordisk. Any breach of the ABPI Code is taken extremely seriously and it is essential that all regulatory actions are robust, fair and transparent.”

ABPI Vice-President, Susan Rienow, Country President of Pfizer, will temporarily take on the roles and responsibilities of the ABPI President until a new President is chosen by the ABPI Board.

The association had appointed Sahota, general manager and corporate vice president of Novo Nordisk UK as its new president in April last year.


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...